In-depth studies revealed that Runx2 promoted cancer progression by inducing the epithelial–mesenchymal transition (EMT) progress in breast cancer15, thyroid carcinoma16, and hepatocellular carcinoma (HCC)17. The gene discussed is RUNX2; the disease is hepatocellular carcinoma.